ABL1 and neurodegenerative disease: However, in all planned treatments, issues related to adverse reactions and side effects of the c-Abl inhibitors have to be rigorously analyzed since a long-term treatment with these drugs is foreseen in the case of neurodegenerative diseases, such as PD.